涉及一种新颖氮杂普林斯型环化反应Ñ -acyliminium离子和酰胺被报告四氢嘧啶并[2,1-的合成一个]异吲哚-2,6-二酮和6,6-一个-dihydroisoindolo [2,1-一个]喹唑啉-5,11-二酮衍生物,产率极好。该策略的特点是试剂价格低廉,反应条件温和,N-杂环骨架的无金属合成。此外,合成后的修饰导致其前所未有的三唑、四环二氮杂环戊二烯[ def ]菲-1,4(9 a 1 H )-二酮和羰基衍生物的形成。
[EN] TETRAHYDROISOQUINOLIN-2-YL-(QUINAZOLIN-4-YL) METHANONE COMPOUNDS AS CANCER CELL GROWTH INHIBITORS [FR] COMPOSÉS DE TÉTRAHYDROISOQUINOLIN-2-YL-(QUINAZOLIN-4-YL)MÉTHANONE À TITRE D'INHIBITEURS DE CROISSANCE DES CELLULES CANCÉREUSES
Selective Palladium-Catalyzed Aminocarbonylation of Olefins with Aromatic Amines and Nitroarenes
作者:Xianjie Fang、Ralf Jackstell、Matthias Beller
DOI:10.1002/anie.201308455
日期:2013.12.23
Various olefins can be smoothly transformed in the presence of a Pd‐based catalyst system and (hetero)aromaticamines or nitroarenes to synthetically interesting amides in good yields and often with high regioselectivity (see scheme). Combining this atom‐efficient procedure with established functionalizations of the resulting products allows the efficient preparation of quinolines.
The Synthesis and Anticonvulsant Activity of someω-Phthalimido-N-phenylacetamide and Propionamide Derivatives
作者:Zeynep Soyer、Fatma Sultan Kılıc、Kevser Erol、Varol Pabuccuoglu
DOI:10.1002/ardp.200300823
日期:2004.2
pharmacophores which are known to produce potent anticonvulsant compounds, sixteen ω‐phthalimido‐N‐phenylacetamide and propionamidederivatives bearing substituents at positions 2 or 2, 6 on N‐phenyl ring have been synthesized. The structural confirmation of the title compounds was achieved by interpretation of spectral and analytical data. The anticonvulsantactivity of the title compounds was determined against
在这项研究中,通过结合苯胺和 N ',N' - 邻苯二甲酰甘氨酰胺药效团已知可产生有效的抗惊厥化合物,十六种 ω - 邻苯二甲酰亚胺 - N - 苯基乙酰胺和丙酰胺衍生物在 N - 苯环的 2 或 2、6 位带有取代基已经合成。标题化合物的结构确认是通过对光谱和分析数据的解释来实现的。标题化合物的抗惊厥活性是在 100 mg/kg 剂量水平的小鼠中针对最大电休克发作测定的。初步筛选结果表明,ω-邻苯二甲酰亚胺-N-苯基乙酰胺和丙酰胺核对最大电休克发作具有明显的抗惊厥活性。
SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS
申请人:HAMANAKA S. ERNEST
公开号:US20080090829A1
公开(公告)日:2008-04-17
The present invention is directed at substituted heteroaryl- and phenylsulfamoyl compounds, pharmaceutical compositions containing such compounds and the use of such compounds as peroxisome proliferator activator receptor (PPAR) agonists. PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans. The compounds are also useful for the treatment of negative energy balance (NEB) and associated diseases in ruminants.
Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone derivatives represented by formula (I), pharmacologically acceptable salts thereof, and compositions containing such compounds are described. Methods for treating hyperproliferative disorders by administering the compounds are also described. 1,2,3,4-tetrahydroisoquinoline derivatives for making tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone compounds are also described.